Cosmo Pharmaceuticals NV (COPN):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Cosmo Pharmaceuticals NV (COPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3462)・商品コード:DATA904C3462
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:30
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of various gastro-intestinal tract, inflammatory bowel diseases, colon infections and colon diagnosis, among others. Cosmo also provides SIC 8000, a submucosal injectable composition for extracting polyps and adenomas; and other products. The company manufactures products for oral administration such as tablets, capsules, powders and syrups; topical dosage forms such as emulsions, gels, ointments and injectables, among others. Its manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland.

Cosmo Pharmaceuticals NV (COPN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cosmo Pharmaceuticals NV, Medical Devices Deals, 2012 to YTD 2018 9
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
AIMM Therapeutics Enters Into Co-Development Agreement With Cosmo Pharma 11
Licensing Agreements 12
EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 12
Pharmascience Enters into Licensing Agreement with Cosmo Pharma 13
Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 15
Cosmo Pharma Enters into Licensing Agreement with BioMAS 16
Equity Offering 17
Cosmo Pharma Raises USD215.5 Million in Private Placement of Shares 17
Cosmo Pharma Raises USD103.4 Million in private placement of Shares 18
Cassiopea Raises USD186.4 Million in Initial Public Offering of Shares 19
Acquisition 20
Cosmo Pharma Acquires 15.4% Stakes in BioMAS for USD2 Million 20
Cosmo Pharmaceuticals NV – Key Competitors 21
Cosmo Pharmaceuticals NV – Key Employees 22
Cosmo Pharmaceuticals NV – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Jul 26, 2018: Cosmo Half-Year report 2018 24
Corporate Communications 25
May 17, 2017: Cosmo Pharmaceuticals Announces Appointment Of Non-Executive Board Member 25
Legal and Regulatory 26
Apr 12, 2018: Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant 26
Product News 27
05/18/2017: Salix Pharmaceuticals Announces the Publication of a Study Evaluating the Safety and Efficacy of UCERIS (budesonide) Tablets for Induction of Remission in Patients with Active Mild to Moderate Ulcerative Colitis Refractory to Mesalamine Therapy 27
Product Approvals 28
Nov 01, 2017: Cosmo Pharmaceuticals Provides Update on Commercialization of Rifamycin SV MMX 28
Oct 23, 2017: FDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX) 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cosmo Pharmaceuticals NV, Deals By Therapy Area, 2012 to YTD 2018 8
Cosmo Pharmaceuticals NV, Medical Devices Deals, 2012 to YTD 2018 9
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AIMM Therapeutics Enters Into Co-Development Agreement With Cosmo Pharma 11
EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 12
Pharmascience Enters into Licensing Agreement with Cosmo Pharma 13
Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 15
Cosmo Pharma Enters into Licensing Agreement with BioMAS 16
Cosmo Pharma Raises USD215.5 Million in Private Placement of Shares 17
Cosmo Pharma Raises USD103.4 Million in private placement of Shares 18
Cassiopea Raises USD186.4 Million in Initial Public Offering of Shares 19
Cosmo Pharma Acquires 15.4% Stakes in BioMAS for USD2 Million 20
Cosmo Pharmaceuticals NV, Key Competitors 21
Cosmo Pharmaceuticals NV, Key Employees 22
Cosmo Pharmaceuticals NV, Subsidiaries 23

List of Figures
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cosmo Pharmaceuticals NV, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Cosmo Pharmaceuticals NV (COPN):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3462)販売に関する免責事項を必ずご確認ください。
★調査レポート[Cosmo Pharmaceuticals NV (COPN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆